查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703310

抗藥性癲癇市場－全球產業規模、佔有率、趨勢、機會和預測（按治療類型、最終用戶、地區和競爭細分，2020 年至 2030 年）

Drug-Resistant Epilepsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球抗藥性癲癇市場價值為 18.5 億美元，預計到 2030 年將達到 24.4 億美元，預測期內年複合成長率(CAGR) 為 4.72%。在強大的研發活動的推動下，該市場不斷發展，致力於滿足對傳統抗癲癇藥物 (AED) 反應不足的患者未滿足的需求。

市場概覽
預測期 2026-2030
2024年市場規模 18.5億美元
2030年市場規模 24.4億美元
2025-2030 年複合年成長率 4.72%
成長最快的領域 神經調節療法
最大的市場 北美洲

癲癇是一種以反覆發作為特徵的神經系統疾病，影響全球大量人口。抗藥性癲癇（也稱為難治性癲癇）是指患者儘管使用兩種或兩種以上適當的抗癲癇藥物治療，但仍會繼續癲癇發作的病例。該領域代表著大量未滿足的臨床需求，推動全球市場格局的創新和投資。

關鍵市場促進因素

癲癇盛行率不斷上升

主要市場挑戰

複雜且異質性的疾病概況

主要市場趨勢

神經影像技術的進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球抗藥性癲癇市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（神經調節療法、抗癲癇藥物、苯二氮平類藥物、切除性癲癇手術、特定代謝治療、特定基因治療、免疫療法）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按治療類型
    • 按最終用戶
    • 按地區

第5章：亞太地區抗藥性癲癇市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按治療類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲抗藥性癲癇市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美抗藥性癲癇市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：南美洲抗藥性癲癇市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章：中東和非洲抗藥性癲癇市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球抗藥性癲癇市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • UCB SA
  • Jazz Pharmaceuticals
  • LivaNova PLC
  • NeuroPace, Inc
  • Avenue Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Marinus Pharmaceuticals
  • PTC Therapeutics
  • Aquestive Therapeutics
  • Neuroelectrics

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16867

Global Drug-Resistant epilepsy market was valued at USD 1.85 billion in 2024 and is projected to reach USD 2.44 billion by 2030, registering a compound annual growth rate (CAGR) of 4.72% during the forecast period. This market continues to evolve, driven by robust research and development activities focused on addressing the unmet needs of patients who exhibit inadequate response to conventional anti-epileptic drugs (AEDs).

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.85 Billion
Market Size 2030USD 2.44 Billion
CAGR 2025-20304.72%
Fastest Growing SegmentNeuromodulation Therapy
Largest MarketNorth America

Epilepsy, a neurological condition characterized by recurrent seizures, affects a significant global population. Drug-resistant epilepsy-also known as refractory epilepsy-refers to cases in which patients continue to experience seizures despite treatment with two or more appropriate AEDs. This segment represents a substantial unmet clinical need, propelling innovation and investment across the global market landscape.

Key Market Drivers

Increasing Prevalence of Epilepsy

The rising global incidence of epilepsy is a primary factor fueling market growth. According to the World Health Organization (WHO), approximately 50 million individuals worldwide are affected by epilepsy. Of this population, an estimated 30% do not respond adequately to standard anti-seizure therapies, resulting in drug-resistant forms of the disorder.

As global demographics shift toward an aging population, the overall prevalence of epilepsy is expected to rise, contributing to an increased burden of drug-resistant cases. This trend underscores the urgent need for advanced therapeutic solutions tailored to this difficult-to-treat patient group.

Additionally, while up to 70% of epilepsy patients could potentially achieve seizure control with appropriate treatment, approximately 75% of individuals in low-income regions lack access to essential medications. This treatment gap highlights the critical importance of early diagnosis, improved access to care, and continued innovation in therapeutic options designed specifically for drug-resistant epilepsy.

Key Market Challenges

Complex and Heterogeneous Disease Profile

One of the most significant challenges in treating drug-resistant epilepsy is the condition's complex and heterogeneous nature. The disorder comprises a wide range of seizure types, each with distinct etiologies, clinical presentations, and treatment responses. This variability complicates efforts to develop universally effective therapies.

The evolving nature of drug-resistant epilepsy further contributes to its clinical complexity. Seizure patterns and drug efficacy may change over time, requiring continuous reassessment and adaptation of treatment strategies. As a result, the development of standardized interventions remains a major hurdle, necessitating a more personalized approach to care.

Key Market Trends

Advancements in Neuroimaging Technologies

Innovations in neuroimaging are significantly enhancing diagnostic and therapeutic capabilities in the drug-resistant epilepsy market. These advanced imaging techniques are transforming clinical approaches by providing deeper insights into brain structure and function.

Modern Magnetic Resonance Imaging (MRI) technologies-including functional MRI (fMRI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy (MRS)-offer high-resolution views of brain activity, connectivity, and subtle structural abnormalities. These tools are instrumental in identifying epileptic foci and guiding surgical or targeted treatment options.

Positron Emission Tomography (PET) also plays a crucial role by detecting metabolic irregularities in brain regions associated with seizure activity. Enhanced by advanced radiotracers and image processing methods, PET imaging facilitates more accurate diagnosis and localization of epileptic zones.

In addition, Single-Photon Emission Computed Tomography (SPECT) is widely used to assess cerebral blood flow during seizures, helping clinicians pinpoint seizure origins and inform personalized treatment planning. Collectively, these advancements are fostering a more precise and effective management paradigm for drug-resistant epilepsy.

Key Market Players

  • UCB S.A.
  • Jazz Pharmaceuticals
  • LivaNova PLC
  • NeuroPace, Inc
  • Avenue Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Marinus Pharmaceuticals
  • PTC Therapeutics
  • Aquestive Therapeutics
  • Neuroelectrics

Report Scope:

In this report, the Global Drug-Resistant Epilepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug-Resistant Epilepsy Market, By Treatment Type:

  • Neuromodulation Therapy
  • Antiseizure Medications
  • Benzodiazepines
  • Resective Epilepsy Surgery
  • Specific Metabolic Treatment
  • Specific Genetic Treatment
  • Immunotherapy

Drug-Resistant Epilepsy Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Drug-Resistant Epilepsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug-Resistant Epilepsy Market.

Available Customizations:

Global Drug-Resistant Epilepsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Drug-Resistant Epilepsy Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment Type (Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment, Specific Genetic Treatment, Immunotherapy)
    • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.3. By Region
    • 4.2.4. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Treatment Type
    • 4.3.2. By End User
    • 4.3.3. By Region

5. Asia Pacific Drug-Resistant Epilepsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type
    • 5.2.2. By End User
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Drug-Resistant Epilepsy Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.2. By End User
    • 5.3.2. India Drug-Resistant Epilepsy Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment Type
        • 5.3.2.2.2. By End User
    • 5.3.3. Australia Drug-Resistant Epilepsy Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment Type
        • 5.3.3.2.2. By End User
    • 5.3.4. Japan Drug-Resistant Epilepsy Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment Type
        • 5.3.4.2.2. By End User
    • 5.3.5. South Korea Drug-Resistant Epilepsy Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment Type
        • 5.3.5.2.2. By End User

6. Europe Drug-Resistant Epilepsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Drug-Resistant Epilepsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Germany Drug-Resistant Epilepsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Spain Drug-Resistant Epilepsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User
    • 6.3.4. Italy Drug-Resistant Epilepsy Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By End User
    • 6.3.5. United Kingdom Drug-Resistant Epilepsy Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By End User

7. North America Drug-Resistant Epilepsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Drug-Resistant Epilepsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Drug-Resistant Epilepsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Drug-Resistant Epilepsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User

8. South America Drug-Resistant Epilepsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Drug-Resistant Epilepsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Argentina Drug-Resistant Epilepsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Colombia Drug-Resistant Epilepsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User

9. Middle East and Africa Drug-Resistant Epilepsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Drug-Resistant Epilepsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Saudi Arabia Drug-Resistant Epilepsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. UAE Drug-Resistant Epilepsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Drug-Resistant Epilepsy Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. UCB S.A.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Jazz Pharmaceuticals
  • 14.3. LivaNova PLC
  • 14.4. NeuroPace, Inc
  • 14.5. Avenue Therapeutics
  • 14.6. Xenon Pharmaceuticals Inc.
  • 14.7. Marinus Pharmaceuticals
  • 14.8. PTC Therapeutics
  • 14.9. Aquestive Therapeutics
  • 14.10. Neuroelectrics

15. Strategic Recommendations

16. About Us & Disclaimer